Loading
A phase 2 trial of Ivonescimab, Olaparib in ovarian cancer, run by Akeso, now recruiting.
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer is a phase 2 interventional study registered as NCT06686030 by Akeso, with 150 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10. Interventions recorded: AK112 low dose, Chemotherapy, Olaparib, AK112 high dose. Conditions listed: Platinum-sensitive Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares Akeso, Ivonescimab, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares Akeso, Ivonescimab.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Olaparib, Ovarian cancer.